drugset / Trial / NCT00153166
ARREST PAD (Peripheral Arterial Disease)
Phase 2/3
Completed
76 enrolled
Brigham and Women's Hospital
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This trial will test the hypothesis that inflammation and insulin resistance contribute to reduced walking distance in subjects with intermittent claudication by impairing vascular reactivity and skeletal muscle metabolic function.
Timeline
- Start
- 2004-01
- Primary completion
- 2010-11
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 80 mg | Oral |
| Subject | Pioglitazone | Small molecule | 30 mg | Oral |